Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

By T. Nyström, M. Gutniak, Qimin Zhang, Fan Zhang, Jens J. Holst, B. Ahrén, Å. Sjöholm. American Journal of Physiology. Endocrinology and Metabolism, 2004

679 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/4e2e89c500d4877bba16b61e0e771c30e0ea0efa

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. D. J. Drucker

In Endocrinology, Diabetes and Metabolism

1. Josephine M. Egan
2. Wook Kim
3. M. Nauck
4. D. J. Drucker
5. F. Reimann
6. F. Gribble
7. Ralph DeFronzo
8. J. Meier

Citations in the corpus

• The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, background): “In particular, GLP-1 infusion significantly ameliorates endothelial dysfunction in patients with T2DM with an established coronary artery disease (Nyström et al., 2004).”
• Endothelial Dysfunction and Diabetes: Effects on Angiogenesis, Vascular Remodeling, and Wound Healing (2012, background): “There are several clinical trials investigating the therapeutic regulation of endothelial function in patients with type 2 diabetes mellitus [320–322, 325–328].”
• Glucagon-like peptide 1 (GLP-1) (2019, background): “These include an increase of cardiomyocyte survival via inhibition of apoptosis [614,615], amelioration of endothelial dysfunction [612,616], improvement of regional, and global cardiac output following injury and heart failure [614,617e619] (Figure 7).”